| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/25/2007 | US7273843 Methods of treating allergy by administering interleukin-17 receptor |
| 09/25/2007 | US7273752 Expression vector wherein said expression vector comprises a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an antigen protein or peptide, a polynucleotide encoding a cell binding element, |
| 09/25/2007 | US7273751 Comprises nucleotide sequences associated with expression vector coding endothelial growth factor for use in diagnosis and treatment of tumor angiogenesis, inflammation, diabetic retinopathy, arthritis and psoriasis; wound healing agent |
| 09/25/2007 | US7273744 Heparanase-like polypeptides |
| 09/25/2007 | US7273728 Fermenting an appropriate microorganism using glucose as a carbon source and operating two chromatographic separation steps wherein ion exchange chromatography is followed by hydrophobic interaction chromatography, wherein the diphtheria toxin has a purity of at least 98%. |
| 09/25/2007 | US7273727 Eukaryotic host cell containing a nucleic acid sequence coding for a bivalent or a multivalent glycosylated compound having two or more single polypeptide chain antigen binding regions linked to a prodrug-activating enzyme; transgenic nonhuman mammal having the sequence |
| 09/25/2007 | US7273726 Compounds, compositions and methods for the treatment of diseases characterized by A-33 related antigens |
| 09/25/2007 | US7273725 Human and mammalian stem cell-derived neuron survival factors |
| 09/25/2007 | US7273724 Also producing the polypeptide by DNA recombinant technology |
| 09/25/2007 | US7273722 Insertion of cleavage sites in non-critical regions of the toxins which are susceptible to protease activity in non-target tissues and single chain forms activated by proteases in the target; botulism and tetanus toxins; confine activity to target site; side effect reduction |
| 09/25/2007 | US7273710 Method for screening MCH receptor antagonist/agonist |
| 09/25/2007 | US7273706 Decreased expression level of the protein in said test sample relative to the expression level of the protein in a normal sample is indicative of a testicular tumor or a predisposition to a testicular tumor. |
| 09/25/2007 | US7273698 Defects in periaxin associated with myelinopathies |
| 09/25/2007 | US7273695 HIV immunoassays using synthetic envelope polypeptides |
| 09/25/2007 | US7273622 Soft gel capsule, beta-carotene; vitamin E; yellow beeswax;a mixture of mono-, di, tri-glycerides of 16 to 18 carbon chain length and polyglycerol oleate; rice bran oil |
| 09/25/2007 | US7273615 Reaction solution for cell-free protein synthesis, method of preparing the same, and protein synthesis method using the same |
| 09/25/2007 | US7273614 Inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells. |
| 09/25/2007 | US7273612 Soluble inhibitors of vascular endothelial growth factor and use thereof |
| 09/25/2007 | US7273611 Proteinase K resistant surface protein of neisseria meningitidis |
| 09/25/2007 | US7273609 Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
| 09/25/2007 | US7273607 Comprises vitamins, minerals, amino acids, herbs, and essential oils; side effect reduction |
| 09/25/2007 | US7273606 Solubilized CoQ-10 and carnitine |
| 09/25/2007 | CA2484240C Packaged ocular irrigating solution bag |
| 09/25/2007 | CA2306257C 5-azaquinoxaline-based compounds and modulation of serine/threonine protein kinase function |
| 09/25/2007 | CA2294649C Bovine adenovirus type 3 genome |
| 09/25/2007 | CA2256516C Peptides |
| 09/25/2007 | CA2200967C Pharmaceutical compositions |
| 09/25/2007 | CA2192442C Complementary adenoviral vector systems and cell lines |
| 09/25/2007 | CA2173592C Stem cell proliferation factor |
| 09/25/2007 | CA2143898C A process for reactivating purified membrane proteins by freezing them |
| 09/25/2007 | CA2132868C Method of using antibodies against human chorionic gonadotropin-related determinants to lyse, measure and enrich malignant cells |
| 09/25/2007 | CA2112701C Proteins s polypeptides and uses thereof |
| 09/25/2007 | CA2054686C Treatment of polycystic ovarian disease |
| 09/21/2007 | CA2581109A1 Modulator of gamma secretase |
| 09/20/2007 | WO2007106746A2 Formulations for ecallantide |
| 09/20/2007 | WO2007106585A1 Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| 09/20/2007 | WO2007106494A2 Methods and compositions for treatment of diastolic heart failure |
| 09/20/2007 | WO2007106488A2 Modulators of gluconeogenesis |
| 09/20/2007 | WO2007106385A2 Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment |
| 09/20/2007 | WO2007106121A2 Design and construction of dimeric concanavalin a mutants |
| 09/20/2007 | WO2007106056A1 Compositions and methods for treating t-cell mediated pathological conditions |
| 09/20/2007 | WO2007105661A1 Enzyme-containing candy |
| 09/20/2007 | WO2007105565A1 Peptide for inhibition of influenza infection, inhibitor of influenza infection, liposome, and prophylactic/therapeutic agent for influenza |
| 09/20/2007 | WO2007105442A1 Therapeutic agent for food intake disorder or water intake disorder |
| 09/20/2007 | WO2007105224A1 Combination of cytokine and cytokine receptor for altering immune system functioning |
| 09/20/2007 | WO2007105199A1 Use of caspases for the preparation of medicaments |
| 09/20/2007 | WO2007105024A1 Pharmaceutical compositions comprising sods and prolamine based peptide fragments |
| 09/20/2007 | WO2007104999A1 Anti-cancer therapy |
| 09/20/2007 | WO2007104946A2 Medicaments and proteins based on tgf-beta monomers for the treatment of wounds |
| 09/20/2007 | WO2007104932A2 Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof |
| 09/20/2007 | WO2007104835A1 Use of a growth-stimulating protein |
| 09/20/2007 | WO2007104786A1 Mixtures of amylin and insulin |
| 09/20/2007 | WO2007104768A2 Di-polymer protein conjugates and processes for their preparation |
| 09/20/2007 | WO2007104737A1 Acylated single chain insulin |
| 09/20/2007 | WO2007104736A2 Acylated single chain insulin |
| 09/20/2007 | WO2007104734A1 Acylated single chain insulin |
| 09/20/2007 | WO2007104567A2 Pegylated mutated clostridium botulinum toxin |
| 09/20/2007 | WO2007104541A2 Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders |
| 09/20/2007 | WO2007104317A1 Methods for local treatment with factor vii |
| 09/20/2007 | WO2007104263A1 An enhancin of hepatitis b virus vaccine and its gene |
| 09/20/2007 | WO2007104196A1 Lhrh antagonist possessing low histamine releasing effect |
| 09/20/2007 | WO2007104173A2 Method for solubilizing, dispersing, and stabilizing materials, products manufactured according to said method, and use thereof |
| 09/20/2007 | WO2007104149A1 Method of preventing or reducing the risk or incidence of cancer using neural thread protein based peptides |
| 09/20/2007 | WO2007090630A3 Peptide aptamer for neutralizing the binding of platelet antigene specific antibodies and diagnostic and therapeutic applications containing the same |
| 09/20/2007 | WO2007089454A3 Methods for enhancing skin treatments |
| 09/20/2007 | WO2007087759A3 Pharmaceutical composition of microspheres for preventing diabetic foot amputation |
| 09/20/2007 | WO2007083101A3 Use in an alternative treatment of cancer |
| 09/20/2007 | WO2007079457A3 Materials and methods for immunizing against fiv infection |
| 09/20/2007 | WO2007053644A3 Comparative ligand mapping from mhc class i positive cells |
| 09/20/2007 | WO2007047608A3 Fibrin targeted therapeutics |
| 09/20/2007 | WO2007041513A3 Conserved membrane activator of calcineurin (cmac), a novel therapeutic protein and target |
| 09/20/2007 | WO2007028394A3 Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort |
| 09/20/2007 | WO2007019860A3 Gdnf derived peptides |
| 09/20/2007 | WO2007014749A3 Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor |
| 09/20/2007 | WO2007008671A3 Methods for treating fus1 related disorders |
| 09/20/2007 | WO2007002572A3 Nattokinase for reducing whole blood viscosity |
| 09/20/2007 | WO2007000601A8 Gene regulation |
| 09/20/2007 | WO2006136160A3 Proteases for pharmaceutical use |
| 09/20/2007 | WO2006130687A3 Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor |
| 09/20/2007 | WO2006130626A3 Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period |
| 09/20/2007 | WO2006130554A3 Methods of treating hepatitis c virus |
| 09/20/2007 | WO2005092068A3 Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase |
| 09/20/2007 | WO2005027871A3 Method for production of bioresorbable microparticles microparticles thus obtained and use thereof |
| 09/20/2007 | WO2005011590A3 Compositions and methods for restoring sensitivity to treatment with her2 antagonists |
| 09/20/2007 | WO2004069176A3 Polymer conjugates of mutated neublastin |
| 09/20/2007 | WO2004009834A3 Novel nucleic acids and secreted polypeptides |
| 09/20/2007 | WO2004004649A3 Compositions and methods for the treatment of immune related diseases |
| 09/20/2007 | WO2003011823A3 Crfr1 selective ligands |
| 09/20/2007 | US20070219526 Restenosis Therapy Using Mesenchymal Stem Cells |
| 09/20/2007 | US20070219357 Chemically modified G-CSF |
| 09/20/2007 | US20070219356 Controlling cell proliferation, cell differentiation; immobilization; prelude to bone marrow transplants; stability, solubility, enhanced circulating half-life and plasma residence times |
| 09/20/2007 | US20070219354 Assays using amyloid precursor proteins with modified beta-secretase cleavage sites to monitor beta-secretase activity |
| 09/20/2007 | US20070219352 Fibrinogen from transgenic animals |
| 09/20/2007 | US20070219347 Meningitidis B serogroup; amino acid sequence encoded by nucleotides 564043 to 565882 of sequence 1; monoclonal antibodies; vaccine antigens |
| 09/20/2007 | US20070219225 Pharmaceutical Compositions For The Prevention And Treatment Of Atherosclerosis |
| 09/20/2007 | US20070219194 Phenylalanine derivatives |
| 09/20/2007 | US20070219177 Agent for treatment of cerebral ischemic diseases |
| 09/20/2007 | US20070219157 Complete nutrient medium for use as a cosmetic and cosmetic use thereof |
| 09/20/2007 | US20070219154 Methods for preventing and/or treating a cell proliferative disorder |
| 09/20/2007 | US20070219151 Methods and compositions for inhibiting the function of polynucleotide sequences |